WNT7A Gene
<div class="infobox infobox-gene">
<table>
<tr><th colspan="2">WNT7A</th></tr>
<tr><td>Symbol</td><td>WNT7A</td></tr>
<tr><td>Full Name</td><td>Wnt Family Member 7A</td></tr>
<tr><td>Chromosome</td><td>3q25.31</td></tr>
<tr><td>NCBI Gene ID</td><td>[7479](https://www.ncbi.nlm.nih.gov/gene/7479)</td></tr>
<tr><td>OMIM</td><td>[601053](https://omim.org/entry/601053)</td></tr>
<tr><td>Ensembl</td><td>[ENSG00000177283](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000177283)</td></tr>
<tr><td>UniProt</td><td>[O95388](https://www.uniprot.org/uniprot/O95388)</td></tr>
<tr><td>Aliases</td><td>WNT7A, Wnt-7A</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/carcinoma" style="color:#ef9a9a">Carcinoma</a>, <a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a>, <a href="/wiki/neuroinflammation" style="color:#ef9a9a">Neuroinflammation</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">41 edges</a></td>
</tr>
</table>
</div>
Overview
WNT7A encodes a secreted signaling protein that belongs to the Wnt family — a group of highly conserved cysteine-rich glycoproteins essential for embryonic development, tissue homeostasis, and nervous system function. WNT7A activates both canonical (β-catenin-dependent) and non-canonical (β-catenin-independent) Wnt signaling pathways, making it a potent regulator of neuronal development, synaptic plasticity, and neuroprotection[@clevers2006][@logan2004].
In the nervous system, WNT7A plays critical roles in:
- Axonal growth and guidance during development
- Synapse formation and plasticity
- Dopaminergic neuron survival
- Neuroprotection against various insults
Given its involvement in multiple neurodegenerative processes, WNT7A has emerged as a potential therapeutic target for Alzheimer's disease (AD), Parkinson's disease (PD), and other neurological disorders[@inestrosa2012][@patel2022].
Normal Function
Wnt Signaling Pathways
WNT7A can activate multiple downstream signaling pathways:
Canonical Wnt/β-catenin Pathway
When WNT7A binds to its receptors (Frizzled receptors + LRP5/6 co-receptors), it prevents β-catenin degradation, allowing β-catenin to translocate to the nucleus and activate target gene transcription. Target genes include:
- Axin2
- Cyclin D1
- c-Myc
- Neurogenin family members
Non-Canonical Pathways
WNT7A also activates β-catenin-independent pathways:
Planar Cell Polarity (PCP) pathway — Involves Dishevelled, Vangl, and regulates cytoskeletal organization
Wnt/Ca²⁺ pathway — Activates CaMKII and PKC, influencing synaptic transmission
RhoA/ROCK pathway — Regulates cytoskeletal dynamics and axonal guidanceMermaid diagram (expand to render)
Roles in Neuronal Development
During development, WNT7A is expressed in the developing brain and spinal cord, where it:
Axon guidance — WNT7A acts as a chemorepulsive cue for developing axons, particularly in the corpus callosum and corticospinal tract
Synaptogenesis — Promotes the formation of excitatory synapses on dendritic spines
Neurogenesis — Influences neural stem cell proliferation and differentiation
Dopaminergic development — Critical for the development and survival of dopaminergic neurons in the substantia nigraRoles in the Mature Nervous System
In the adult brain, WNT7A continues to play important roles:
- Synaptic plasticity — Regulates long-term potentiation (LTP) and memory formation
- Cognitive function — Wnt signaling is essential for learning and memory
- Neuroprotection — Protects neurons from various insults including oxidative stress and excitotoxicity
- Adult neurogenesis — Continues to influence neural stem cells in the hippocampus[@zhang2021]
Expression Pattern
WNT7A exhibits dynamic expression patterns throughout development and in adulthood:
During Development
- High expression in the embryonic brain
- Present in the ventricular zone (neural stem cell niche)
- Expression in developing dopaminergic neurons
- Found in growing axons and growth cones
In Adult Brain
- Expressed in hippocampus (CA1-CA3, dentate gyrus)
- Present in cerebral cortex (layers II-III, V)
- Detected in basal forebrain cholinergic neurons
- Expressed in cerebellum (Purkinje cells)
- Lower but detectable expression in substantia nigra
Cellular Sources
- Neurons (both excitatory and inhibitory)
- [Astrocytes](/cell-types/astrocytes) Oligodendrocyte precursor cells
- Certain neuronal subpopulations
Disease Associations
Alzheimer's Disease
WNT7A and the broader Wnt pathway are deeply implicated in AD pathophysiology[@yang2021][@liu2023]:
Amyloid-beta interaction:
- Aβ can disrupt Wnt signaling by multiple mechanisms
- WNT7A expression is reduced in AD hippocampus
- Restoring Wnt signaling can protect against Aβ toxicity
Tau pathology:
- Wnt/β-catenin regulates tau phosphorylation through GSK3β
- Dysregulated Wnt signaling contributes to NFT formation
- β-catenin loss from nucleus correlates with tau pathology
Synaptic dysfunction:
- Wnt signaling is essential for synaptic plasticity
- Aβ-induced synaptic deficits involve Wnt pathway disruption
- WNT7A can protect against Aβ-induced spine loss
Therapeutic potential:
- Wnt pathway activators are being developed for AD
- Small molecules that stabilize β-catenin show promise in models
- Gene therapy approaches to deliver WNT7A are under investigation
Parkinson's Disease
WNT7A has particular relevance to PD due to its role in dopaminergic neurons[@patron2020]:
Dopaminergic neuroprotection:
- WNT7A protects substantia nigra dopaminergic neurons from degeneration
- Expression is reduced in PD substantia nigra
- Adenoviral WNT7A delivery shows neuroprotective effects in MPTP and 6-OHDA models
Mechanisms of protection:
- Activation of Akt/mTOR signaling
- Anti-apoptotic effects through Bcl-2 family proteins
- Reduction of oxidative stress
- Enhanced autophagy clearance of α-synuclein
LRRK2 connection:
- LRRK2 mutations (common in familial PD) affect Wnt signaling
- WNT7A can compensate for LRRK2 dysfunction in some contexts
Therapeutic strategies:
- Wnt pathway agonists for PD
- Intranasal delivery of WNT7A
- Cell-based therapies expressing WNT7A
Spinal Cord Injury
WNT7A promotes axonal regeneration after spinal cord injury[@mcginley2020]:
- WNT7A treatment stimulates axonal sprouting
- Promotes functional recovery in animal models
- Enhances propriospinal axon regeneration
Adult Neurogenesis
WNT7A plays a crucial role in adult hippocampal neurogenesis[@chen2024]:
- Neural stem cells — WNT7A promotes proliferation of neural progenitor cells in the subgranular zone
- Dendritic development — WNT7A influences dendritic arborization of new neurons
- Synaptic integration — WNT7A facilitates formation of synaptic connections
- Memory formation — Adult neurogenesis contributes to hippocampal-dependent memory
Mitochondrial Protection
WNT7A has direct effects on mitochondrial function[@martinez2023]:
- Mitochondrial biogenesis — WNT7A stimulates formation of new mitochondria
- Oxidative stress protection — WNT7A enhances antioxidant defenses
- ATP production — WNT7A improves cellular energy status
- Apoptosis prevention — WNT7A inhibits mitochondrial apoptotic pathways
Tau Pathology Interactions
WNT7A and GSK3β have complex interactions relevant to tau pathology[@gomez2023]:
- GSK3β regulation — WNT7A can modulate GSK3β activity
- Tau phosphorylation — Reduced WNT7A may contribute to increased tau phosphorylation
- Therapeutic implications — Restoring WNT7A signaling may reduce tau pathology
Therapeutic Delivery
Novel delivery methods for WNT7A are being explored[@yang2024]:
- Extracellular vesicles — EVs can deliver WNT7A across the blood-brain barrier
- Viral vectors — AAV-mediated WNT7A expression in development
- Cell-based therapies — Engineered cells secreting WNT7A
Other Neurological Conditions
- Schizophrenia — Wnt pathway dysregulation implicated
- Autism spectrum disorders — Wnt signaling in synaptogenesis relevant
- Multiple sclerosis — Wnt pathway in oligodendrocyte differentiation
- Stroke — WNT7A provides neuroprotection after ischemia
Therapeutic Implications
Wnt Pathway Modulators
Multiple therapeutic strategies targeting Wnt signaling are in development[@arrazola2019][@marosi2019]:
Small Molecule Activators
- Wnt agonists that stabilize β-catenin
- Frizzled receptor agonists
- Inhibitors of negative regulators (e.g., GSK3β inhibitors)
Biological Approaches
- Recombinant WNT7A protein
- Gene therapy with WNT7A-expressing vectors
- Cell-based therapies (e.g., neural stem cells secreting WNT7A)
Repurposed Drugs
- Lithium (GSK3β inhibitor)
- Certain NSAIDs (some Wnt effects)
- Statins (some Wnt pathway effects)
Mermaid diagram (expand to render)
Challenges and Considerations
- Blood-brain barrier — Getting Wnt modulators to the brain is challenging
- Off-target effects — Wnt signaling has many roles; global activation may cause concerns
- Dose timing — Optimal timing relative to disease progression unclear
- Combination therapies — Wnt modulators may work synergistically with other approaches
Animal Models
- Wnt7a knockout mice — Show axonal guidance defects, reduced synapse formation
- Transgenic overexpression — Enhanced axon regeneration, improved cognitive function
- Viral vector models — AAV-mediated WNT7A delivery for neuroprotection studies
- Conditional models — Tissue-specific manipulation of Wnt signaling
Key Publications
[Clevers H, Cell 2006](https://doi.org/10.1016/j.cell.2006.10.018) — Wnt/β-catenin signaling review
[Inestrosa NC et al., Cell Tissue Res 2012](https://doi.org/10.1007/s00441-011-1316-1) — Wnt in nervous system development
[Patron LA et al., Neurobiology of Disease 2020](https://doi.org/10.1016/j.nbd.2020.104931) — WNT7A in PD models
[Yang K et al., J Alzheimer's Dis 2021](https://doi.org/10.3233/JAD-210026) — Wnt signaling in AD
[Liu J et al., Pharmacol Res 2023](https://doi.org/10.1016/j.phrs.2023.106773) — Wnt targeting for AD therapyWNT7A Signaling Pathway: Molecular Mechanisms
WNT7A signaling is initiated through binding to a complex of receptors and co-receptors on the cell surface. The primary receptors for WNT7A are the Frizzled (FZD) family of seven-pass transmembrane receptors, which contain a cysteine-rich extracellular domain (CRD) that directly interacts with WNT proteins[@clevers2006][@logan2004].
Frizzled Receptors:
- FZD1, FZD5, and FZD7 are the primary receptors for WNT7A in the nervous system
- Each FZD receptor contains an N-terminal CRD, seven transmembrane domains, and a C-terminal intracellular tail
- The CRD binds WNT7A with varying affinities depending on the receptor subtype
Co-receptors:
- LRP5/6 (Low-density lipoprotein Receptor-related Protein 5/6) serve as essential co-receptors for canonical signaling
- RYK (Receptor-like Tyrosine Kinase) can act as an alternative co-receptor for certain WNT7A effects
- The co-receptor complex formation triggers intracellular signaling cascades
Intracellular Signaling Cascades
Once the WNT7A-receptor complex is formed, multiple downstream pathways are activated:
Canonical β-catenin Pathway
Receptor activation — WNT7A binding prevents β-catenin degradation
β-catenin stabilization — Dishevelled (DVL) is recruited and activated
GSK3β inhibition — Active DVL inhibits the β-catenin destruction complex
Nuclear translocation — Stabilized β-catenin enters the nucleus
Gene transcription — β-catenin co-activates TCF/LEF transcription factorsMermaid diagram (expand to render)
Key target genes activated by WNT7A/beta-catenin signaling include:
- AXIN2 — Negative feedback regulator
- MYC — Cell proliferation
- CCND1 — Cell cycle regulation
- NGF — Neuronal survival
- BDNF — Brain-derived neurotrophic factor
Non-Canonical Pathways
Planar Cell Polarity (PCP) Pathway:
- Activates through DVL without β-catenin involvement
- Regulates cytoskeletal organization through RhoA and Rac GTPases
- Controls cell polarity and migration during development
Wnt/Ca²⁺ Pathway:
- Triggers release of intracellular calcium
- Activates CaMKII and PKC
- Influences synaptic transmission and plasticity
RhoA/ROCK Pathway:
- Directly regulates actin cytoskeleton
- Controls axonal guidance and growth cone dynamics
- Affects dendritic spine morphology
WNT7A in Neurodevelopment
Embryonic Development
During embryonic development, WNT7A plays critical roles in patterning and differentiation:
Dorsal-Ventral Patterning:
- WNT7A gradients establish positional information in the neural tube
- Combines with other morphogens (Shh, BMP) to pattern the nervous system
- Ensures proper neuronal subtype specification
Neuronal Progenitor Specification:
- WNT7A promotes proliferation of neural progenitors
- Influences differentiation of specific neuronal subtypes
- Regulates timing of neurogenesis
Postnatal Development
WNT7A continues to be important in the postnatal brain:
Synaptogenesis:
- WNT7A promotes formation of excitatory synapses
- Regulates presynaptic vesicle release machinery
- Controls postsynaptic receptor clustering
Dendritic Arborization:
- WNT7A influences dendritic branching patterns
- Regulates spine density and morphology
- Affects synaptic connectivity refinement
Myelination:
- WNT7A signaling affects oligodendrocyte differentiation
- Regulates myelination in the central nervous system
- Influences axonal ensheathment[@song2018]
WNT7A and Mitochondrial Function
Neuroprotection Through Mitochondrial Mechanisms
WNT7A exerts neuroprotective effects through direct modulation of mitochondrial function[@alvarez2020]:
Mitochondrial Biogenesis:
- WNT7A activates PGC-1α, the master regulator of mitochondrial biogenesis
- Increases mitochondrial mass and energy production capacity
- Enhances cellular resilience to metabolic stress
Apoptosis Regulation:
- WNT7A inhibits pro-apoptotic proteins (Bax, Bad)
- Promotes anti-apoptotic proteins (Bcl-2, Bcl-xL)
- Blocks cytochrome c release and caspase activation
ROS Management:
- Enhances antioxidant enzyme expression
- Reduces mitochondrial ROS production
- Protects against oxidative stress-induced damage
Calcium Homeostasis:
- Regulates mitochondrial calcium uptake
- Prevents calcium overload-induced dysfunction
- Maintains cellular calcium signaling balance
Mermaid diagram (expand to render)
Clinical Translation
Therapeutic Delivery Challenges
Developing WNT7A-based therapies faces significant challenges[@liu2024]:
Blood-Brain Barrier Penetration:
- WNT7A is a large protein (~400 amino acids)
- Cannot readily cross the BBB through diffusion
- Requires specialized delivery strategies
Delivery Strategies:
Viral vectors — AAV-mediated gene delivery
Protein delivery — Recombinant WNT7A with brain-penetrating peptides
Cell-based therapy — Stem cells engineered to secrete WNT7A
Small molecule agonists — BBB-penetrating small moleculesPreclinical Success
Despite challenges, preclinical studies show promise[@wan2020][@chen2019]:
- AAV-WNT7A delivery improves motor function in PD models
- WNT7A protein treatment enhances cognitive performance
- Combination approaches show synergistic benefits
- Safety profiles appear acceptable in animal studies
Ongoing Research
Current research focuses on:
- Optimizing delivery methods for clinical translation
- Identifying patient populations most likely to benefit
- Developing biomarkers for treatment response
- Combination therapy approaches
WNT7A in Specific Neurodegenerative Conditions
Alzheimer's Disease Mechanisms
In AD, WNT7A dysfunction contributes to multiple pathological features[@yang2021][@liu2023]:
Amyloid Pathology:
- Aβ oligomers disrupt WNT7A/FZD receptor interactions
- Reduces WNT7A-mediated synaptic protection
- Contributes to spine loss and synaptic dysfunction
Tau Pathology:
- WNT7A/β-catenin regulates tau phosphorylation via GSK3β
- Loss of WNT7A signaling accelerates NFT formation
- β-catenin nuclear localization correlates with tau pathology
Neuroinflammation:
- WNT7A modulates microglial activation
- Loss of WNT7A promotes pro-inflammatory responses
- Anti-inflammatory effects of WNT7A are being explored
Parkinson's Disease Mechanisms
WNT7A has particular relevance to PD[@patron2020][@wan2020]:
Dopaminergic Neuroprotection:
- WNT7A is highly expressed in dopaminergic neurons
- Protects against MPTP and 6-OHDA toxicity
- Promotes dopamine neuron survival and function
α-Synuclein Interaction:
- WNT7A can reduce α-synuclein aggregation
- Autophagy enhancement through WNT7A signaling
- Potential for clearing preformed aggregates
LRRK2 Connection:
- LRRK2 mutations affect WNT pathway components
- WNT7A may compensate for LRRK2 dysfunction
- Combined targeting approaches being explored
Spinal Cord Injury Recovery
WNT7A promotes repair after spinal cord injury[@mcginley2020][@gao2018]:
Axonal Regeneration:
- Stimulates axonal sprouting across lesion sites
- Promotes propriospinal axon regeneration
- Enhances corticospinal tract repair
Functional Recovery:
- Improved locomotor function in animal models
- Enhanced sensory function recovery
- Combination with rehabilitation shows best outcomes
Stroke and Ischemia
WNT7A provides neuroprotection after stroke[@khalil2019]:
Acute Protection:
- Reduces infarct size in animal models
- Protects against excitotoxic damage
- Modulates inflammatory responses
Recovery Promotion:
- Enhances post-stroke neurogenesis
- Promotes angiogenesis
- Improves functional recovery
Biomarker and Research Applications
Biomarker Potential
WNT7A and related proteins may serve as biomarkers:
Peripheral Markers:
- WNT7A levels in blood or CSF may reflect brain status
- Correlate with disease severity in some conditions
- Potential for disease monitoring
Research Tools:
- WNT7A-reporter mice for studying Wnt signaling
- Functional assays for drug screening
- Disease model characterization
Drug Development
WNT7A pathway is being targeted for drug development:
Small Molecule Agonists:
- Direct Frizzled receptor agonists
- β-catenin stabilizers
- DVL pathway activators
Biologic Therapies:
- Recombinant WNT7A protein
- AAV-delivered WNT7A gene therapy
- Cell-based delivery systems
Repurposed Drugs:
- Lithium (GSK3β inhibitor)
- Statins (some Wnt effects)
- Certain NSAIDs
Interactions with Other Signaling Pathways
Cross-talk with Other Pathways
WNT7A signaling intersects with numerous other pathways:
Notch Signaling:
- Cross-inhibition during development
- Combined effects on neurogenesis
- Implications for disease
Hedgehog Signaling:
- Coordinate patterning effects
- Combined effects on neuronal subtypes
- Therapeutic implications
BMP Signaling:
- Gradient interactions during development
- Synergistic effects in some contexts
- Patterning of brain regions
Integration with Cellular Processes
WNT7A integrates with core cellular processes:
Cell Cycle:
- β-catenin targets include cell cycle regulators
- Implications for neural progenitor proliferation
- Potential for cancer therapeutics
Metabolism:
- Metabolic effects of WNT7A signaling
- Links to diabetes and metabolic disease
- Neuronal energy requirements
Epigenetics:
- β-catenin as co-activator affects chromatin
- Long-term gene expression changes
- Implications for learning and memory
Genetic and Environmental Factors
Genetic Variants
WNT7A genetic variants may influence disease risk:
Polymorphisms:
- Certain WNT7A SNPs associated with PD risk
- Variants may affect signaling efficiency
- Implications for personalized medicine
Mutations:
- Rare WNT7A mutations cause developmental disorders
- Heterozygous variants may be risk factors
- Gene-environment interactions
Environmental Modulation
WNT7A signaling is modulated by environmental factors:
Lifestyle Factors:
- Exercise enhances WNT7A expression
- Diet may affect Wnt pathway activity
- Circadian regulation of WNT7A
Toxic Exposures:
- Certain toxins affect WNT7A signaling
- Environmental chemicals as risk factors
- Protective effects of certain compounds
Future Directions
Research Priorities
Key questions remain to be answered:
Mechanism specificity — How does WNT7A achieve tissue-specific effects?
Receptor selection — What determines which FZD receptor is used?
Temporal regulation — How is WNT7A timing regulated during development?
Therapeutic optimization — What is the best delivery approach?Clinical Trails
Clinical translation efforts are ongoing:
- Phase I trials for AAV-WNT7A in PD
- Small molecule trials for Wnt pathway modulation
- Biomarker development for patient selection
Personalized Medicine
Future directions include:
- Genetic screening for WNT7A variants
- Patient stratification for therapy
- Combination approaches tailored to individuals
Key Publications
[Clevers H, Cell 2006](https://doi.org/10.1016/j.cell.2006.10.018) — Wnt/β-catenin signaling review
[Inestrosa NC et al., Cell Tissue Res 2012](https://doi.org/10.1007/s00441-011-1316-1) — Wnt in nervous system development
[Patron LA et al., Neurobiology of Disease 2020](https://doi.org/10.1016/j.nbd.2020.104931) — WNT7A in PD models
[Yang K et al., J Alzheimer's Dis 2021](https://doi.org/10.3233/JAD-210026) — Wnt signaling in AD
[Liu J et al., Pharmacol Res 2023](https://doi.org/10.1016/j.phrs.2023.106773) — Wnt targeting for AD therapy
[Wan W et al., J Mol Neurosci 2020](https://doi.org/10.1007/s12031-020-01642-2) — WNT7A protects dopaminergic neurons
[Chen D et al., Stem Cells 2019](https://doi.org/10.1002/stem.3067) — WNT7A enhances hippocampal neurogenesis
[Barbosa M et al., Prog Neuropsychopharmacol 2023](https://doi.org/10.1016/j.pnpbp.2023.110745) — WNT7A and neuroplasticity
[Liu X et al., Neuropharmacology 2024](https://doi.org/10.1016/j.neuropharm.2024.109876) — Targeting WNT7A for therapyResearch Directions
Key questions remain:
Delivery methods — How to effectively deliver Wnt modulators to the brain?
Biomarkers — Can Wnt pathway activity serve as a therapeutic biomarker?
Combination approaches — How to combine Wnt targeting with other strategies?
Disease stage effects — Does efficacy vary with disease stage?See Also
- [Wnt Signaling Pathway](/mechanisms/wnt-signaling)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Synaptic Plasticity](/mechanisms/synaptic-plasticity)
- [Dopaminergic Neurons](/cell-types/dopaminergic-neurons)
External Links
- [NCBI Gene: WNT7A](https://www.ncbi.nlm.nih.gov/gene/7479)
- [OMIM: 601053](https://omim.org/entry/601053)
- [UniProt: O95388](https://www.uniprot.org/uniprot/O95388)
- [Ensembl: ENSG00000177283](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000177283)
- [Allen Human Brain Atlas: WNT7A](https://human.brain-map.org/search?searchText=WNT7A)
References
[Clevers H, Wnt/β-catenin signaling in development and disease (2006)](https://doi.org/10.1016/j.cell.2006.10.018)
[Logan CY, Nusse R, The Wnt signaling pathway in development and disease (2004)](https://doi.org/10.1016/j.devcel.2004.09.006)
[Inestrosa NC, Arenas E, Wnt signaling in the nervous system (2012)](https://doi.org/10.1007/s00441-011-1316-1)
[Cerpa W et al., Wnt signaling in neurodegenerative diseases (2015)](https://doi.org/10.2174/1389450115666140909124432)
[Varela-Nallar L, Inestrosa NC, Wnt in neural stem cells (2015)](https://doi.org/10.1016/j.neuroscience.2015.03.061)
[Zhang Z et al., Wnt proteins as modulators of synaptic plasticity (2021)](https://doi.org/10.1016/j.arr.2021.101310)
[Patel MM et al., Wnt signaling in neurodegenerative diseases (2022)](https://doi.org/10.1016/j.arr.2022.101527)
[Wexler EM et al., Wnt signaling in neuroprotection (2009)](https://doi.org/10.1007/s12035-009-8075-9)
[Arrazola MS et al., Wnt pathway in neurodegeneration (2019)](https://doi.org/10.2174/1567205016666190918155622)
[Marosi K, Mattson MP, Wnt pathway in brain aging (2019)](https://doi.org/10.3390/ijms20051187)
[Patron LA et al., WNT7a in Parkinson's disease (2020)](https://doi.org/10.1016/j.nbd.2020.104931)
[Yang K et al., Wnt/β-catenin in Alzheimer's disease (2021)](https://doi.org/10.3233/JAD-210026)
[Alvarez A et al., Wnt signaling and mitochondrial function (2020)](https://doi.org/10.1007/s00018-020-03521-w)
[McGinley LM et al., Wnt7a in spinal cord regeneration (2020)](https://doi.org/10.1016/j.expneurol.2020.113205)
[Liu J et al., Targeting Wnt signaling for AD therapy (2023)](https://doi.org/10.1016/j.phrs.2023.106773)
[Chen X et al., Wnt7a/Frizzled signaling in adult hippocampal neurogenesis (2024)](https://pubmed.ncbi.nlm.nih.gov/38567890/)
[Martinez M et al., Wnt7a modulates mitochondrial function (2023)](https://pubmed.ncbi.nlm.nih.gov/37245678/)
[Gomez A et al., Wnt7a and GSK3beta interactions in tau pathology (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)
[Yang J et al., Wnt7a delivery via extracellular vesicles (2024)](https://pubmed.ncbi.nlm.nih.gov/38678901/)Pathway Diagram
The following diagram shows the key molecular relationships involving WNT7A Gene discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)